LNTH

EX-99.1

2 lnth-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Lantheus Reports Third Quarter 2026 Financial Results

• Worldwide revenue of $389.9 million in the third quarter of 2026

• GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025

• Adjusted fully diluted earnings per share of $1.68, compared to $1.27 in the third quarter of 2025

• FDA approves TAUKLARIFY™ (florquinitau F-18 injection); an F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive impairment being assessed for Alzheimer’s disease

• FDA grants final approval for BRAVNETSA™ (lutetium Lu 177 dotatate); the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA® for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

• Announced on August 3, 2026 that the Company has entered into a definitive agreement to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares of the Company in an all-cash transaction that represents a total transaction value of up to approximately $8.0 billion

BEDFORD, Mass., November 5, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its third quarter ended September 30, 2026.

In addition, and as previously announced, Lantheus entered into a definitive agreement on August 3, 2026 to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares of Lantheus for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights (“CVRs”) providing for up to $12.00 per share in potential additional cash payments, subject to achievement of specified commercial milestones for Lantheus’ products through 2030. The transaction represents a total per share consideration of up to $114.50 and a total transaction value of up to approximately $8.0 billion. Together, Curium and Lantheus are positioned to create a radiopharmaceutical company spanning diagnostics and therapeutics, with the infrastructure and capabilities to serve patients in more than 70 countries. The Board of Directors of Lantheus has unanimously approved the transaction. Additional information regarding the transaction is available in the Company’s Current Report on Form 8-K filed with the SEC on August 4, 2026.

In connection with the pending transaction, Lantheus is suspending its previously issued full year 2026 financial guidance and will not be hosting a conference call in connection with its third quarter 2026 results.

Summary Financial Results

Three Months Ended September 30,

(in millions, except per share data - unaudited)

2026

2025

% Change

Worldwide revenue

$

389.9

$

384.0

1.5

%

GAAP net income

$

22.4

$

27.8

(19.4

%)

GAAP fully diluted earnings per share

$

0.33

$

0.41

(19.5

%)

Adjusted net income (non-GAAP)

$

115.1

$

85.7

34.3

%

Adjusted fully diluted earnings per share (non-GAAP)

$

1.68

$

1.27

32.3

%

Third Quarter 2026

• Worldwide revenue increased 1.5% to $389.9 million compared to the same period in 2025.

• Sales of PYLARIFY were $238.9 million, a decrease of 0.7%.

Page 1 of 11

• Sales of Neuraceq were $45.6 million, an increase of 123.0%.

• Sales of DEFINITY were $85.7 million, an increase of 4.8%.

• Operating income decreased 26.2% to $32.2 million. Adjusted operating income (non-GAAP) increased 28.1% to $153.2 million.

• Fully diluted earnings per share decreased 19.5% to $0.33, compared to fully diluted earnings per share of $0.41 in the prior year period. Adjusted fully diluted earnings per share (non-GAAP) increased 32.3% to $1.68, compared to $1.27 in the prior year period.

• Net cash provided by operating activities and free cash flow were $102.0 million and $99.9 million, respectively.

Balance Sheet

• At September 30, 2026, the Company's cash and cash equivalents were $683.6 million, compared to $359.1 million at December 31, 2025.

• The Company currently has access to up to $750.0 million from a revolving line of credit.

Recent Business Highlights

• Received CMS Transitional Pass-Through payment status and a permanent HCPCS code, each effective October 1, 2026, for PYLARIFY® TruVu™ (piflufolastat F18), supporting the Company’s previously announced phased geographic commercial launch.

• Received FDA approval for TAUKLARIFY (florquinitau F-18 injection), an F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive impairment being assessed for Alzheimer’s disease. The Company intends to continue supporting Alzheimer’s disease therapeutic programs through its Pharma Solutions business while assessing the appropriate path toward broader commercial availability.

• Received final FDA appr

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.ce06d217.1786388640.83a3914

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

EX-99.1

2 lnth-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

• Strong start to the year with worldwide revenue of $377.3 million in the first quarter 2026

• GAAP fully diluted earnings per share of $1.80, compared to $1.02 in the first quarter of 2025

• Adjusted fully diluted earnings per share of $1.46, compared to $1.53 in the first quarter of 2025

• FDA approves PYLARIFY TruVuTM (piflufolastat F18); phased geographic launch planned to begin in the fourth quarter of 2026

• FDA tentative approval for Lutetium Lu 177 Dotatate (PNT2003); expected to be the first radioequivalent for the treatment of gastroenteropancreatic neuroendocrine tumors

• Reaffirmed previously issued corporate guidance for full year 2026 revenue and adjusted fully diluted earnings per share

BEDFORD, Mass., May 7, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its first quarter ended March 31, 2026.

“Our first quarter results demonstrate disciplined execution across the business, with strong performance from PYLARIFY, Neuraceq, and DEFINITY, and continued progress against the priorities that underpin our long-term strategy,” said Mary Anne Heino, Chief Executive Officer of Lantheus. “During the quarter, we secured FDA approval for PYLARIFY TruVu and achieved tentative approval for PNT2003. For the remainder of 2026, we are focused on sustaining our leadership in PSMA PET as we prepare for the PYLARIFY TruVu conversion later this year, expanding our Alzheimer’s imaging portfolio, and advancing our prioritized pipeline. At the same time, we will remain disciplined in our capital deployment, prioritizing radiodiagnostics while evaluating the best path to maximize value from our radiotherapeutic assets – all as we lay the groundwork for growth acceleration beginning in 2027.”

Summary Financial Results

Three Months Ended March 31,

(in millions, except per share data - unaudited)

2026

2025

% Change

Worldwide revenue

$

377.3

$

372.8

1.2

%

GAAP net income

$

118.4

$

72.9

62.3

%

GAAP fully diluted earnings per share

$

1.80

$

1.02

76.5

%

Adjusted net income (non-GAAP)

$

95.8

$

109.5

(12.5

%)

Adjusted fully diluted earnings per share (non-GAAP)

$

1.46

$

1.53

(4.6

%)

First Quarter 2026

• Worldwide revenue increased 1.2% to $377.3 million compared to the same period in 2025.

• Sales of PYLARIFY were $240.9 million, a decrease of 6.5%.

• Sales of Neuraceq were $35.4 million.

• Sales of DEFINITY were $84.6 million, an increase of 6.8%.

• Operating income decreased 20.3% to $81.3 million. Adjusted operating income (non-GAAP) decreased 10.5% to $129.1 million.

Page 1 of 11

• Fully diluted earnings per share increased 76.5% to $1.80, compared to fully diluted earnings per share of $1.02 in the prior year period. Adjusted fully diluted earnings per share (non-GAAP) decreased 4.6% to $1.46, compared to $1.53 in the prior year period.

• Net cash provided by operating activities and free cash flow were $125.1 million and $121.9 million, respectively.

Balance Sheet

• At March 31, 2026, the Company's cash and cash equivalents were $498.6 million, including proceeds of $31.4 million from the sale of the Company’s single-photon emission computerized tomography (“SPECT”) business to SHINE Technologies, LLC (“SHINE”) on January 1, 2026, compared to $359.1 million at December 31, 2025.

• The Company currently has access to up to $750.0 million from a revolving line of credit.

Recent Business Highlights

• Received FDA approval for PYLARIFY TruVuTM (piflufolastat F18), a new formulation of PYLARIFY®, the Company’s market‑leading PSMA PET imaging agent, designed to enhance manufacturing efficiency and supply flexibility; a phased geographic commercial launch is planned to begin in the fourth quarter of 2026 to align with coding, coverage, payment, and customer and PMF readiness.

• Completed the divestiture of the legacy SPECT business to SHINE (effective January 1, 2026), a decisive action taken to focus on PET radiodiagnostics and simplify the Company’s operating model.

• Achieved FDA tentative approval for PNT2003, which upon full approval would be the first radioequivalent to Lutetium Lu 177 Dotatate for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP‑NETs); launch timing will consider the following factors: the timing of FDA approval, the expiration of the 30‑month Hatch‑Waxman stay and disposition of the related legal proceedings, as well as manufacturing and commercial strategy to ensure launch success.

• The FDA extended the PDUFA date for LNTH‑2501(Ga 68 edotreotide), the Company’s PET diagnostic imaging kit for somatostatin receptor‑positive neuroendocrine tumors (NETs),